Previous 10 | Next 10 |
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting Clinical study data suggests Tyvaso® improved forced vital capacity, an important measure of lung function, in patients with pulmonary hypertension associated with interstitial lung disea...
United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N...
United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. ...
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant Expanded collaboration combines CollPlant's proprietary BioInk that is based on its recombinant human collagen (rhCollagen...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 16, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt , Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the compa...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 11, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell , M.D. to its Board of Directors as an independent director, effective as of September 10, 2020 . ...
The FDA accepts for review United Therapeutics' (NASDAQ: UTHR ) supplemental marketing application seeking approval to use Tyvaso (treprostinil) Inhalation Solution to treat pulmonary hypertension associated with interstitial lung disease, a disorder affecting ~30K Americans. More news...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso ® (t...
The following slide deck was published by United Therapeutics Corporation in conjunction with this Read more ...
The Nasdaq Composite closed above 11,000 for the first time signaling possible overvaluation. Here are three stocks with low P/Es in the index: Sprouts Farmers Market (SFM), United Therapeutics (UTHR), and Virtu Financial (VIRT). Last Thursday, the Nasdaq Composite closed above 11,000 for t...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...